非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
分子式C23H19Cl2N3O4 |
InChIKeyXNRZJPQTMQZBCE-SFHVURJKSA-N |
CAS号1037592-40-7 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
胆道肿瘤 | 临床3期 | 日本 | - | |
结直肠癌 | 临床2期 | 日本 | - | |
肾细胞癌 | 临床1期 | 日本 | - |
临床2期 | 104 | (夢蓋鹽窪廠壓醖餘夢簾): HR = 0.439 (95% CI, 0.2254 ~ 0.8535), P-Value = 0.0131 更多 | 积极 | 2023-05-26 | |||
placebo | |||||||
临床2期 | 106 | (築構網憲淵繭窪築網憲) = significant improvement 鹹齋衊構選積艱築範蓋 (構糧鏇鏇鏇繭醖範製築 ) 达到 | 积极 | 2023-01-24 | |||
placebo | |||||||
临床1期 | - | (壓餘簾壓獵築壓壓蓋糧) = Common treatment-related adverse events were increased ALT/AST, malaise, nausea, hypertension, and grade 1 or grade 2 fevers. 艱觸憲觸遞壓鑰築壓蓋 (觸繭壓鑰鏇顧遞繭積範 ) 更多 | 积极 | 2018-06-01 | |||
临床1期 | 17 | (簾餘積廠壓艱製簾醖蓋) = Common treatment-related adverse events were increased ALT/AST, malaise, nausea, hypertension and fever of Grade 1 or 2. 艱鹽憲糧網築齋醖齋遞 (構鏇鏇糧蓋製艱積鑰觸 ) 更多 | 积极 | 2018-02-26 |